K562/GM-CSF vaccine

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameK562/GM-CSF vaccine
Drug Alias NameK562/GM-C SFK562-GMCG-9962GM-K562
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsMyelodysplastic SyndromesNeoplasm MetastasisColorectal Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesJohns Hopkins UniversityNational Cancer InstituteSidney Kimmel Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesSidney Kimmel Cancer CenterJohns Hopkins UniversityNational Cancer Institute
Inactive CompaniesDana-Farber Cancer Institute
Active IndicationsLeukemia, Myelogenous, Chronic
Inactive IndicationsMyelodysplastic SyndromesNeoplasm MetastasisColorectal Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksN/A